(2R)-2-[[(2R)-2-AMINO-3-(1-METHOXYCARBONYLINDOL-3-YL)PROPANOYL]-[(2S)-2-[[(2R,6S)-2,6-DIMETHYLPIPERIDINE-1-CARBONYL]AMINO]-4,4-DIMETHYLPENTANOYL]AMINO]HEXANOIC ACID
| 中文名称 | (2R)-2-[[(2R)-2-AMINO-3-(1-METHOXYCARBONYLINDOL-3-YL)PROPANOYL]-[(2S)-2-[[(2R,6S)-2,6-DIMETHYLPIPERIDINE-1-CARBONYL]AMINO]-4,4-DIMETHYLPENTANOYL]AMINO]HEXANOIC ACID |
|---|---|
| 中文同义词 | (2R)-2-[[(2R)-2-[[(2S)-2-[[(2R,6S)-2,6-DIMETHYLPIPERIDINE-1-CARBONYL]AMINO]-4,4-DIMETHYLPENTANOYL]AMINO]-3-(1-METHOXYCARBONYLINDOL-3-YL)PROPANOYL]AMINO]HEXANOIC ACID;化合物 T10595;(R)-2-((R)-2-((S)-2-((2R,6S)-2,6-二甲基哌啶-1-甲酰胺基)-4,4-二甲基戊酰胺基)-3-(1-(甲氧羰基)-1H-吲哚-3-基)丙酰胺基)己酸;PERFEMIKER]BQ-788,98%;化合物 BQ-788 |
| 英文名称 | N-CIS-2,6-DIMETHYLPIPERIDINOCARBONYL-BETA-TBU-ALA-D-TRP(1-METHOXYCARBONYL)-D-NLE-OH |
| 英文同义词 | N-cis-2,6-DiMethylpiperidinocarbonyl-b-tBu-Ala-D-Trp(1-Methoxycarbonyl)-D-Nle-OH;(2R)-2-[[(2R)-2-AMINO-3-(1-METHOXYCARBONYLINDOL-3-YL)PROPANOYL]-[(2S)-2-[[(2R,6S)-2,6-DIMETHYLPIPERIDINE-1-CARBONYL]AMINO]-4,4-DIMETHYLPENTANOYL]AMINO]HEXANOIC ACID;BQ788, CID 3081333;D-Norleucine, N-[(cis-2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-L-leucyl-1-(methoxycarbonyl)-D-tryptophyl- (9CI);D-Norleucine,N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]-,cis-;(2R)-2-[[(2R)-2-[[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]-3-(1-methoxycarbonylindol-3-yl)propanoyl]amino]hexanoicacid;BQ788,BQ 788 |
| CAS号 | 173326-37-9 |
| 分子式 | C34H51N5O7 |
| 分子量 | 641.8 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 173326-37-9.mol |
| 结构式 | ![(2R)-2-[[(2R)-2-AMINO-3-(1-METHOXYCARBONYLINDOL-3-YL)PROPANOYL]-[(2S)-2-[[(2R,6S)-2,6-DIMETHYLPIPERIDINE-1-CARBONYL]AMINO]-4,4-DIMETHYLPENTANOYL]AMINO]HEXANOIC ACID 结构式](CAS/GIF/173326-37-9.gif) |
(2R)-2-[[(2R)-2-AMINO-3-(1-METHOXYCARBONYLINDOL-3-YL)PROPANOYL]-[(2S)-2-[[(2R,6S)-2,6-DIMETHYLPIPERIDINE-1-CARBONYL]AMINO]-4,4-DIMETHYLPENTANOYL]AMINO]HEXANOIC ACID 性质
| 密度 | 1.23±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：10mM |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.40±0.10(Predicted) |
| 颜色 | 白色至米白色 |
(2R)-2-[[(2R)-2-AMINO-3-(1-METHOXYCARBONYLINDOL-3-YL)PROPANOYL]-[(2S)-2-[[(2R,6S)-2,6-DIMETHYLPIPERIDINE-1-CARBONYL]AMINO]-4,4-DIMETHYLPENTANOYL]AMINO]HEXANOIC ACID 用途与合成方法
IC50: 1.2 nM (ETB)
BQ-788 potently and competitively inhibits 125 I-labeled ET-1 binding to ETB receptors in human Girrardi heart cells (hGH) with an IC 50 of 1.2 nM, but only poorly inhibits the binding to ETA receptors in human neuro-blastoma cell line SK-N-MC cells (IC 50 , 1300 nM). BQ-788 shows no agonistic activity up to 10 μM and competitively inhibits thevasoconstriction induced by an ETB-selective agonist (pA2, 8.4). BQ-788 also inhibits several bioactivities of ET-1, such as bronchoconstriction, cell proliferation, and clearance of perfused ET-1.
BQ-788 (3 mg/kg/h, i.v.) completely inhibits a pharmacological dose of ET-1- or sarafotoxin6c (0.5 nmol/kg, i.v.)-induced ETB receptor-mediated depressor, but not pressor responses in conscious rats. Furthermore, BQ-788 markedly increases the plasma concentration of ET-1, which is considered an index of potential ETB receptor blockade in vivo. In Dahl salt-sensitive hypertensive (DS) rats, BQ-788 (3 mg/kg/h, i.v.) increases blood pressure by about 20 mm Hg. It is reported that BQ-788 also inhibits ET-1-induced bronchoconstriction, tumor growth and lipopolysaccharide-induced organfailure. BQ 788 (3 mg/kg) results in an eightfold leftward shift in the ET-1 dose-response curve, suggesting a significant involvement of ETB dilator receptors. Mice are treated with 30 nmol BQ-788 by intraplantar, reduce mechanical hyperalgesia (47% and 42%), thermal hyperalgesia (68% and 76%), oedema (50% and 30%); myeloperoxidase activity (64% and 32%), and overt-pain like behaviours. Additionally, intraplantar treatment with clazosentan or BQ-788 decreases spinal (45% and 41%) and peripheral (47% and 47%) superoxide anion production as well as spinal (47% and 47%) and peripheral (33% and 54%) lipid peroxidation, respectively.